Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Klara Kvorning Ternov1, Peter Busch Østergren1,2, Mikkel Fode1,2

  • 1Afdeling for Urinvejssygdomme, Københavns Universitetshospital - Herlev og Gentofte Hospital.

Ugeskrift for Laeger
|October 28, 2022
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply: Clinical Decision-Making Beyond Noninferiority in Office-Based Treatment of Recurrent Low-Grade Ta Bladder Tumors.

The Journal of urology·2026
Same author

A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials.

The journal of sexual medicine·2026
Same author

DaRenCa risk score: A prognostic model for recurrence in clear cell renal cell carcinoma.

BJUI compass·2026
Same author

[Late sequelae after major urological surgery].

Ugeskrift for laeger·2026
Same author

Management of Lymph Node-Positive Renal Cell Carcinoma: Updated Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.

European urology·2026
Same author

Reply to Singh and Srivastav's Letter to the Editor re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2026.01.010.

European urology focus·2026
Same journal

[Mosaicism as a cause of Cowden syndrome].

Ugeskrift for laeger·2026
Same journal

[Thyrotoxic crisis with cardiogenic shock].

Ugeskrift for laeger·2026
Same journal

[Mindfulness-based cognitive therapy in the treatment of depression].

Ugeskrift for laeger·2026
Same journal

[Fitness].

Ugeskrift for laeger·2026
Same journal

[Risk of developing cataract related to fluoroscopy].

Ugeskrift for laeger·2026
Same journal

[Obturator hernia with small bowel ileus presenting as hip pain in an elderly woman].

Ugeskrift for laeger·2026
See all related articles

Men with metabolic syndrome face a higher risk of erectile dysfunction (ED). Screening for metabolic components and managing them is crucial for treating ED effectively.

Area of Science:

  • Endocrinology
  • Urology
  • Cardiovascular Medicine

Background:

  • Metabolic syndrome significantly increases the risk of erectile dysfunction (ED) in men.
  • ED is a common comorbidity in men with metabolic syndrome and its individual components.

Approach:

  • This review synthesizes current understanding of the link between metabolic syndrome and ED.
  • It outlines diagnostic criteria and screening recommendations for ED in this patient population.

Key Points:

  • Metabolic screening (BMI, waist circumference, blood pressure, HbA1c, lipids) is recommended for men with ED.
  • Management of metabolic syndrome components is a primary therapeutic step for ED.
  • Treatment options for ED include lifestyle changes, pharmaceutical therapies, and mechanical devices.

Related Experiment Videos

Conclusions:

  • Addressing metabolic syndrome is fundamental in the comprehensive management of erectile dysfunction.
  • Integrated care focusing on metabolic health can improve ED outcomes.